These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 15264110

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.
    J Immunol Methods; 2007 Apr 10; 321(1-2):19-31. PubMed ID: 17335844
    [Abstract] [Full Text] [Related]

  • 3. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C, Gibassier J, Oger J, Le Page E, Edan G.
    Clin Chim Acta; 2007 Feb 10; 377(1-2):185-91. PubMed ID: 17123498
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
    Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J.
    J Immunol Methods; 2008 Jul 31; 336(2):113-8. PubMed ID: 18511063
    [Abstract] [Full Text] [Related]

  • 7. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G.
    Clin Chim Acta; 2008 May 31; 391(1-2):98-101. PubMed ID: 18249193
    [Abstract] [Full Text] [Related]

  • 8. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.
    Capra R, Sottini A, Cordioli C, Serana F, Chiarini M, Caimi L, Padovani A, Bergamaschi R, Imberti L.
    J Neuroimmunol; 2007 Sep 31; 189(1-2):102-10. PubMed ID: 17619058
    [Abstract] [Full Text] [Related]

  • 9. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A.
    Mult Scler; 2007 Mar 31; 13(2):208-14. PubMed ID: 17439886
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity of interferon beta: differences among products.
    Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P.
    J Neurol; 2004 Jun 03; 251 Suppl 2():II15-II24. PubMed ID: 15264108
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.
    Lapé Nixon M, Matud J, Yeh C, Prince HE.
    J Neuroimmunol; 2009 May 29; 210(1-2):104-7. PubMed ID: 19345423
    [Abstract] [Full Text] [Related]

  • 14. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 15. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T, Sölberg Sørensen P, Rice G.
    J Neurol; 2004 Jun 12; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [Abstract] [Full Text] [Related]

  • 16. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F, Schibeci S, Heard R, Stewart G, Booth D.
    J Immunol Methods; 2006 Mar 20; 310(1-2):20-9. PubMed ID: 16448664
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, Kuenz B, Lutterotti A, Berger T, Deisenhammer F.
    Mult Scler; 2012 May 20; 18(5):610-5. PubMed ID: 22013146
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.